Laron Syndrome

• EMA approval · 2026-03-30
  EMA Authorised: Increlex (Mecasermin) — Esteve Pharmaceuticals, S.A.

  The European Medicines Agency authorised Increlex (mecasermin) for Laron syndrome, with Esteve Pharmaceuticals, S.A. as the marketing author…

• FDA approval · 2025-07-09
  FDA Approved: INCRELEX — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

  FDA approved a supplemental application for Increlex (mecasermin) from Ipsen Biopharmaceuticals, Inc., resulting in updated labeling for the…

• CLINICAL_TRIALS trial_result · 2025-07-02
  Clinical Trial Update: Growth Hormone in a Patient With a Dominant-Negative GHR Mutation [Phase 2]

  Phase 2 trial update evaluating growth hormone treatment in a patient with a dominant-negative growth hormone receptor mutation. Results wer…

• FDA approval · 2019-12-03
  FDA Approved: INCRELEX — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

  The FDA approved a supplemental application for INCRELEX (mecasermin) submitted by Ipsen Biopharmaceuticals, Inc.

• FDA approval · 2013-04-19
  FDA Approved: GENOTROPIN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  FDA supplemental approval for Genotropin (somatropin) from Pfizer, authorizing an approved supplemental application to modify or expand its …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2012-09-13
  Clinical Trial Update: IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome [Phase 2, Phase 3]

  A Phase 2/3 trial evaluating IGF-I and IGFBP-3 therapy for growth hormone insensitivity syndrome (Laron syndrome) in children and adolescent…

• FDA approval · 2012-06-14
  FDA Approved: INCRELEX — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

  FDA approved a supplemental application for INCRELEX (mecasermin) from Ipsen Biopharmaceuticals, reflecting regulatory action for this produ…